Public Health, Disease Prevention & WellnessTakeda’s Zasocitinib Phase 3 Data Shows Clear Skin ResultsBusiness WireDecember 18, 2025December 19, 2025 by Business WireDecember 18, 2025December 19, 2025053 Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of...
